John R Koenig

This inventor holds 33 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 7 EPO patents. Top assignees: Abbott Laboratories Corporation, Abbvie Inc., Abbvie S.a.r.l.. Active years: 2004-2019.

USPTO Granted Patents = 33 (Patent Applications = 8)

% Patents Active = 57.6

CIPO Patents = 4 (Patent Applications = 15)

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.2

ph-index = 7

Forward Citations = 226(Granted Patents)

Company Filing History:

21 out of 4,186

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2004-2019

Loading Chart...

Areas of Expertise:

Pyrrolidines

Cystic Fibrosis Modulators

Tricyclics

Indazole Ureas

Vanilloid Receptor Antagonists

Furo-3-Carboxamide Derivatives

Macrocyclic Pyrimidine Derivatives

Spiro Pyrimidine Derivatives

Azabicyclic Compounds

TRPV1 Antagonists

Pain Treatment Amides

P2X Receptor Inhibitors

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10399940 - Substituted pyrrolidines and methods of use (2019-09-03),

2. 10118916 - Modulators of cystic fibrosis transmembrane conductance regulator protein (2018-11-06),

3. 9981910 - Substituted pyrrolidines and methods of use (2018-05-29),

4. 9969693 - 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use (2018-05-15),

5. 9840513 - Substituted tricyclics and method of use (2017-12-12),

6. 9783527 - Indazole ureas and method of use (2017-10-10),

7. 9777020 - Furo-3-carboxamide derivatives and methods of use (2017-10-03),

8. 9642831 - Substituted chromanes and method of use (2017-05-09),

9. 9452986 - 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use (2016-09-27),

10. 8598220 - Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof (2013-12-03),

11. 8487116 - Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2013-07-16),

12. 8440691 - Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof (2013-05-14),

13. 8436005 - Macrocyclic pyrimidine derivatives (2013-05-07),

14. 8278313 - Macrocyclic spiro pyrimidine derivatives (2012-10-02),

15. 8247413 - Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor (2012-08-21),

Title: Insights into the Innovator John R. Koenig

Introduction: John R. Koenig, based in Chicago, IL, has made significant contributions to the field of pharmaceutical science with a remarkable portfolio of 33 patents. His innovative work has focused primarily on compounds that target cystic fibrosis and related diseases, establishing him as a prominent figure in the biomedical landscape.

Latest Patents: Among his latest innovations are two notable patents. The first involves "Substituted pyrrolidines and methods of use." This invention discloses compounds of Formula (I) aimed at treating cystic fibrosis, detailing their production methods and pharmaceutical compositions. The second patent, "Modulators of cystic fibrosis transmembrane conductance regulator protein," provides compounds of formula (I) that serve as agents in treating various conditions mediated by CFTR, including cystic fibrosis, Sjögren's syndrome, and chronic obstructive lung disease. Both patents highlight his commitment to advancing therapeutic options for patients with these challenging conditions.

Career Highlights: Throughout his career, John has been associated with leading organizations in the pharmaceutical industry, including Abbott Laboratories Corporation and AbbVie Inc. His tenure at these companies has seen him contribute to significant advancements in drug development and innovation.

Collaborations: John R. Koenig has had fruitful collaborations with notable professionals in his field, including Chih-hung Lee and Arthur Gomtsyan. These partnerships have likely amplified his research efforts and contributed to the success of his innovative projects.

Conclusion: John R. Koenig stands out as a dedicated inventor and researcher whose patents reflect his dedication to improving health outcomes for patients afflicted with cystic fibrosis and related conditions. His work continues to inspire advancements in pharmaceutical development, making a lasting impact in the healthcare sector.